BioMarin Provides BMN 673 Program Update
July 25, 2013 at 16:05 PM EDT
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today provided an update on its ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. As of July 24, the RECIST response rate from the ongoing trial is nine out of 18 breast
